In clear cell renal cell carcinoma, IGF2BP3 suppresses cancer sensitivity to CDK4/6 inhibitor palbociclib by stabilizing CDK4 mRNA in an m6A- dependent manner [61]. Here, IGF2BP3 is linked to cancer.